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Abstract
Introduction Standard treatment for
neovascular age-related macular
degeneration (nAMD) is intravitreal
injections of anti-VEGF drugs. Following
multiple injections, nAMD lesions often
become quiescent but there is a high risk of
reactivation, and regular review by hospital
ophthalmologists is the norm. The present
trial examines the feasibility of community
optometrists making lesion reactivation
decisions.
Methods The Effectiveness of Community vs
Hospital Eye Service (ECHoES) trial is a
virtual trial; lesion reactivation decisions were
made about vignettes that comprised clinical
data, colour fundus photographs, and optical
coherence tomograms displayed on a web-
based platform. Participants were either
hospital ophthalmologists or community
optometrists. All participants were provided
with webinar training on the disease, its
management, and assessment of the retinal
imaging outputs. In a balanced design, 96
participants each assessed 42 vignettes; a total
of 288 vignettes were assessed seven times by
each professional group.
The primary outcome is a participant’s
judgement of lesion reactivation compared
with a reference standard. Secondary
outcomes are the frequency of sight
threatening errors; judgements about speciﬁc
lesion components; participant-rated
conﬁdence in their decisions about the
primary outcome; cost effectiveness of
follow-up by optometrists rather than
ophthalmologists.
Discussion This trial addresses an important
question for the NHS, namely whether, with
appropriate training, community optometrists
can make retreatment decisions for patients
with nAMD to the same standard as hospital
ophthalmologists. The trial employed a novel
approach as participation was entirely through
a web-based application; the trial required
very few resources compared with those that
would have been needed for a conventional
randomised controlled clinical trial.
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Introduction
Neovascular age-related macular degeneration
(nAMD) is common and can cause severe sight
loss and blindness. Currently, patients with
nAMD are treated with intravitreal injections of
drugs that inhibit vascular endothelial growth
factor (anti-VEGF).1 These drugs ameliorate the
exudative manifestations of the posterior fundus
and improve the morphological appearance of
the retina, leading to stabilisation or
improvement of visual acuity in most patients.2,3
The nAMD lesion can be rendered quiescent but
re-activation of the lesion is common.
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One of two review strategies are typically used:
(a) review monthly until active disease recurs,
or vision drops or (b) treat even if there is no ﬂuid at the
macula (usual criterion for retreatment) but extend the
interval between review visits. The former is
burdensome for patients and for the National Health
Service (NHS), and the latter leads to overtreatment
with its additional risks and expense. Even without
patients receiving treatment, regular monthly review
requires ophthalmologists’ time and other health service
resources.
While there is no evidence on the effectiveness of
community follow-up by optometrists for nAMD, there is
considerable data supporting their role in the provision of
‘shared care’ with the United Kingdom Hospital Eye
Service (HES) for other eye diseases such as glaucoma,
diabetes, and emergency eye care.4–8
A review outlined different approaches to increase the
capacity in nAMD services across the United Kingdom.9
The case studies in the review show a variety of scenarios.
Many involve extended roles for optometrists and nurse
practitioners but these occur in the HES. The effectiveness
of these management pathways has not yet been formally
evaluated. Some studies have investigated the potential of
remote care, which involves assessments by a retinal
specialist of optical coherence tomograms (OCT) captured
in outreach services.10,11
There is the opportunity in the United Kingdom, and
other countries with a widely available optometric
primary care service, for a shared care scheme for patients
with quiescent nAMD, with community optometrists
taking responsibility for regular review and referring
patients with reactivated nAMD back to eye clinics for
retreatment. Community optometrists already have the
necessary training to recognise nAMD (they are
responsible for the majority of referrals to the HES), and
some United Kingdom community optometric practices
have already invested in the technology for performing
digital colour fundus (CF) and OCT photography and use
these technologies for decisions about diagnosis and
referral. Identifying a reactivated lesion is more difﬁcult
as this requires differentiation of quiescent from active
disease rather than detection of disease in a previously
normal eye. The skill and ability of optometrists to
differentiate quiescent from active nAMD has not been
formally evaluated nor, as far as we are aware, has a
shared care management scheme for nAMD.
Long-term studies12–17 indicate that quiescent
neovascular lesions frequently reactivate. As the
workload associated with reviewing and treating
nAMD continues to rise, many NHS hospitals are
struggling to provide regular monthly reviews with
around 25% of patients having fewer than 7 visits per
year.18 Therefore, we sought to evaluate whether
community optometrists can be trained to make
decisions about the need for retreatment in patients
with quiescent nAMD with the same accuracy as
ophthalmologists, as a necessary step in establishing the
feasibility of a shared care scheme.
A conventional, parallel-group trial that randomised
patients to retreatment decision making by either
ophthalmologists or optometrists, comparing ensuing
outcomes in the two groups, was not considered feasible
for two reasons. First, patients might be unwilling to
consent to randomisation to decision-making by
optometrists, perceiving it to be potentially risky. Second,
a conventional trial would be expensive and take a long
time. Therefore, the Effectiveness of Community vs
Hospital Eye Service (ECHoES) trial was designed as a
virtual trial. We hypothesised that the ability of suitably
trained optometrists to make correct lesion classiﬁcation
decisions from clinical vignettes would not be inferior to
that of ophthalmologists. The trial design allows lesion
classiﬁcation decisions made by participants in the two
professional groups for the same vignettes to be
compared against each other and against a reference
standard.
Objectives
The objectives of the ECHoES trial are to:
(a) Compare the proportion of lesion classiﬁcation
decisions made by optometrists and ophthalmologists
scored as ‘correct’ (against a reference standard).
(b) Estimate the agreement, and nature of disagreements,
between lesion classiﬁcation decisions made by
optometrists and ophthalmologists.
(c) Estimate the inﬂuence of vignette clinical and demo-
graphic information on lesion classiﬁcation decisions.
(d) Estimate the cost-effectiveness of follow-up in the
community by optometrists compared with follow-up
by ophthalmologists in the HES.
(e) Ascertain the views of patient representatives, opto-
metrists, ophthalmologists, and clinical commis-
sioners on the proposed shared care model.
Materials and methods
Trial design
The ECHoES trial was designed to emulate the
hypothetical parallel-group trial described in Table 1.
However, the ECHoES trial is more analogous to
a cross-over trial than a parallel group trial, since all
vignettes were reviewed by both optometrists and
ophthalmologists, in a randomised balanced incomplete
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block design.19 This well-established design is only
possible with limited permutations of the total number of
vignettes, participants, and vignettes per participant. We
used a total of 288 vignettes. Forty-eight ophthalmologists
and forty-eight optometrists were assigned forty-two
vignettes. The sample of vignettes differed from
participant to participant within each professional group
but each vignette was assigned to seven participants
((48 × 42)/7= 288). Pairs of participants from each
profession were assigned exactly the same selection of
vignettes.
The trial has been approved by a NHS Research Ethics
Committee (ref 11/129/195) and is registered (ISRCTN
07479761). All professional and qualitative research
participants gave written informed consent.
Vignettes (cf. ‘population’)
A database of vignettes for the ECHoES trial was created
from information collected for the IVAN (alternative
treatments to inhibit VEGF in age-related choroidal
neovascularisation) trial, which evaluated alternative
anti-VEGF treatment for nAMD.12,20,21 The trial collected
3-monthly CF and OCT images (held by the Network of
Ophthalmic Reading Centres for the United Kingdom,
NetwORC), characterising lesions with varying levels of
activity including complete quiescence. The vignettes in
the ECHoES trial were populated only with OCTs
captured on spectral domain systems (≈25% of all
available OCT images).
Each vignette consisted of sets of CF and OCT images
from the study eye at two time points (‘baseline’ and
‘index’), with accompanying clinical information and
visual acuity measurements (Figure 1). The baseline set
were images from a study visit when the lesion was
quiescent (ie, all macular tissue compartments were ﬂuid
free). The index set consisted of images from another
study visit at which the lesion could be active or
quiescent. Participants reviewed the images and clinical
information and classiﬁed the lesion as reactivated,
suspicious or quiescent at the index visit. This task is
similar to ‘2-stop’ nAMD service provision in some
hospitals, whereby patients have retinal imaging at one
appointment (without a clinical assessment), followed
by review of the images and recall for a second
appointment only if the lesion is suspicious or has
reactivated.
Images for vignettes were selected as follows.
First, the database was scrutinised to identify OCTs
captured on a spectral domain system. Second, visits were
identiﬁed for which the OCT grading data were
consistent with a quiescent lesion. Finally, a senior grader
from the NetwORC and a retinal specialist reviewed the
proposed ‘baseline’ sets of images; for each conﬁrmed
quiescent lesion, CFs and spectral domain OCTs for other
visits for the same patient were inspected to identify
another study visit for which eligible images were
available. Images had to be of sufﬁcient clarity and
quality to allow interpretation of disease activity by
clinicians.
The clinical information presented in the vignettes can
been seen in Figure 1.
Ophthalmologist and optometrist assessors
(cf. ‘comparator’ and ‘intervention’)
Ophthalmologists were required to have ≥ 3 years post-
registration experience in ophthalmology, have passed
part 1 of the Royal College of Ophthalmologists or the
Diploma in Ophthalmology or equivalent, and have
experience within the AMD service. Optometrists were
required to be fully qualiﬁed, registered with the General
Optical Council (GOC) for ≥ 3 years, and not be
participating in any AMD shared care schemes.
Table 1 Research question components tested in the ECHoES trial compared with a hypothetical parallel group trial
Research question
component
ECHoES (cross over) trial Conventional (parallel group) trial
Population Vignettes representing patients with quiescent nAMD
being monitored for reactivation
Patients with quiescent nAMD being monitored for
nAMD reactivation
Intervention Assessment of vignettes for nAMD reactivation by
a traineda optometrist
Monthly review by a community optometrist, after
training,b to detect nAMD reactivation
Comparator Assessment of vignettes for nAMD reactivation by
a traineda ophthalmologist
Monthly review by an ophthalmologist in the HESb
to detect nAMD reactivation
Outcome Decision about nAMD reactivation (presumed to lead
to appropriate treatment to persevere visual acuity)
Visual acuity
a In the ECHoES trial, both professional groups are required to undergo identical training. b In the parallel group trial, optometrists would be required to
undergo training (not deﬁned here but which could be similar to the training provided in the ECHoES trial). In a pragmatic design, ophthalmologists in the
HES might be assumed to be adequately trained already, since both trials will/would recruit from ophthalmologists who already make such decisions in
the HES.
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Training of participants
Both ophthalmologists and optometrists are qualiﬁed to
detect retinal pathology but optometrists may not have the
skills to detect lesion reactivation. Eligible ophthalmologists
may also not have been fully trained in these skills (despite
the inclusion criterion of ‘have experience within an AMD
service’) since clinical trainees without specialist skills often
staff retina clinics in the HES. Therefore, all participants
received the same training, consisting of two elements: ﬁrst,
participants had to attend two lecture presentations, with
the opportunity to ask questions; second, each participant
had to assess a training set of vignettes and achieve a
criterion level of performance.
Figure 1 Example vignette.
Comparing ophthalmologists’ vs optometrists’ retreatment decisions for wet AMD
J Taylor et al
71
Eye
Lectures (presented as webinars) with standard
‘voice-over’ commentaries were developed to ensure all
participants had the same background knowledge at the
point of starting their assessments. Attendees could ask
questions, which were answered by an expert retinal
specialist hosting the webinar. We intended that the
training package should be well deﬁned and reproducible
so that it could be made widely available for use in the
community. (If the trial hypothesis is refuted, we will
need to examine whether this ﬁnding arose due to
inadequate training and consider how training could be
improved.)
The lectures consisted of short explanatory material
on: (a) the background to the ECHoES trial,
(b) diagnosis, management, and current treatment
pathways in nAMD, (c) the response to treatment
and functional and morphological outcomes to be
expected with current treatments, (d) monitoring of
outcomes and retreatment decision-making criteria,
(e) a range of clinical presentations highlighting
different lesion features and their importance for
retreatment decision-making, and (f) how to use the
web-based application. This material was split over
two sessions, in total lasting 85 min (Supplementary
Table A1).
With regard to the assessment of the vignettes, the
lectures explained that in order for a lesion to be classiﬁed
as reactivated, at least one of the features (sub-retinal
ﬂuid (SRF), intra-retinal cysts (IRC), diffuse retinal
thickening (DRT), blood, and exudates) must be present.
For a lesion to be classiﬁed as quiescent, all of the
features must be absent or must not have increased since
baseline. Figure 2 and Supplementary Table A2 show
the order in which participants were asked to make
judgements about the presence or absence of features
indicating lesion activity.
After participants had attended both webinars, they
received a set of 24 training vignettes selected at random
from the vignette database excluding any vignette pre-
assigned for their main trial assessments. Participants were
required to correctly classify the lesion status for 18 of these
training vignettes, which we considered a credible criterion
for proceeding given the difﬁculty of classifying some
vignettes. If a participant failed to attain this criterion, then
a second attempt was permitted with a different training set
of vignettes. Participants who failed to meet the criterion
twice were withdrawn from the trial. Participants who
attained the pass score could then access the 42 vignettes
assigned to them for their main trial assessments.
A consolidated standards of reporting trials (CONSORT)-
Figure 2 Example responses, feedback summary, and query.
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style diagram shows participant enrolment and ﬂow
through the ECHoES trial (Figure 3).
The reference standard
The reference standard was established from the
judgements of three medical retina expert investigators
(UC, SPH, and TP). The experts independently assessed
the features of index images in exactly the same way as
participants (see above). All three experts assessed all 288
vignettes.
Judgements of experts did not always agree and a
consensus meeting was held to review the 24% of
vignettes for which experts’ classiﬁcations of lesion status
disagreed (over half of disagreements arose from one
expert classifying the lesion as suspicious). At this
meeting, experts reviewed the vignettes together, without
reference to their previous assessments, and reached a
consensus agreement. The reference standard
classiﬁcation was the classiﬁcation agreed by all three
experts: reactivated (142 vignettes, 49.3%), quiescent (141
vignettes, 49.0%), or suspicious (5 vignettes, 1.7%).
Registered health care professionals (n=155)
Ophthalmologist (n=72) Optometrist (n=83)
Withdrawals (n=6):
Target reached so not required (n=3)
Did not attend webinar 1 (n=3)
Completed webinars and allocated their
training vignettes (n=56)
Passed training
first attempt
(n=48)
Passed training
second attempt
(n=2)
Passed training
first attempt
(n=38):
Passed training
second attempt
(n=11):
Completed main trial and included in
analysis dataset (n=48)
Completed main trial and included in
analysis dataset (n=48)
Excluded (n=10):
Not invited to consent (n=1)
Did not return consent form (n=9)
Excluded (n=16):
Did not return consent form (n=16)
Consented (n=62) Consented (n=67)
Withdrawals (n=6):
Target reached so not required (n=1)
Did not want to ‘wait and see’ (n=1)
Did not attend webinar 1 (n=3)
Did not attend webinar 2 (n=1)
Withdrawals (n=6):
Did not complete training (n=2)
Failed training (n=4)
Withdrawals (n=1):
Target reached so not required (n=1)
Withdrawals (n=12):
Did not complete training (n=3)
Failed training (n=8)
Target reached so not required (n=1)
Completed webinars and allocated their
training vignettes (n=61)
Withdrawals (n=2):
Target reached so not required (n=2)
Figure 3 Participant ﬂow. At the start of the trial, we were unsure of how many participants we would need to recruit in order to meet
our target of 48 participants in each group. Therefore, we over recruited at the consent stage and asked a number of participants to
complete the webinar and then ‘wait and see’whether we needed them to participate in the main trial. We also slightly over recruited at
each stage of the trial to account for drop outs. This resulted in a small number of participants being withdrawn at various stages of the
trial because they were no longer required.
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Allowing classiﬁcations of suspicious was unplanned but
required either because of unusual features of the images
or because the experts could not reach consensus.
Outcomes
Primary outcome The primary outcome is a participant’s
judgement of the reactivation status of a lesion from the
index images in a vignette, ie, ‘reactivated’, ‘suspicious’,
or ‘quiescent’, compared with the reference standard. The
number of ‘correct’ assessments (deﬁned as both
participant and reference standard classifying a vignette
as reactivated, or both parties classifying a vignette as
suspicious or quiescent) will be compared between the
two groups.
Secondary outcomes
(a) The frequency of potentially sight threatening errors
(where the reference standard classiﬁcation is reacti-
vated and the participant classiﬁcation is quiescent);
(b) Participants’ judgements about the presence or
absence, and increase from baseline, of lesion compo-
nents (SRF, IRC, DRT, pigment epithelial detachment
(PED), blood, and exudates);
(c) Participant-rated conﬁdence in their decisions about
the primary outcome on a 5-point scale.
Economic evaluation An economic evaluation is being
undertaken alongside the main trial, in accordance with
recognised economic evaluation guidelines,22–24 to
estimate the incremental cost and effectiveness of
optometrists compared with ophthalmologists
performing retreatment assessments for patients with
quiescent nAMD. This will help to determine which
professional group represents the best use of scarce NHS
resources in this context. The main outcome measure is
the cost per accurate lesion classiﬁcation decision.
Data on resource use and costs are being collected
using bespoke costing questionnaires for optometrists,
including sections on staff costs, any equipment and
consumable costs and overheads for optometrist
practices. As some optometrist practices are likely to incur
set up costs associated with assessing the need for
retreatment, the questionnaire speciﬁcally addresses, for
example, what new equipment items would need
to be purchased to perform this additional activity.
The costs associated with training optometrists to
perform the assessments will also be estimated, as this is
important information for policy makers to decide
whether or not to implement shared care for nAMD
across the United Kingdom. For information on the costs
of ophthalmologists performing the assessments, cost
data from the IVAN trial will be used.
The baseline analysis will calculate the average cost and
outcome for each monitoring review of a ‘patient’ by a
participant (ie, lesion classiﬁcation for a vignette and the
consequences of the classiﬁcation). Based on this
information, the incremental cost-effectiveness ratios for
the different assessment options will be derived,
producing an incremental cost per accurate retreatment
decision. Sensitivity analysis will be used to demonstrate
the impact of variation around the key parameters in the
analysis on the baseline cost-effectiveness results. Results
will be expressed in terms of a cost-effectiveness
acceptability curve, showing the likelihood that the
results fall below a given cost-effectiveness threshold.
Qualitative research Qualitative research is also being
undertaken alongside the main trial to explore the
feasibility and acceptability of the proposed shared care
model for patients with quiescent nAMD to different
stakeholders (including ophthalmologists, optometrists,
services users, and commissioners). The aim of the
qualitative research is to identify the different stake
holders’ perspectives on facilitators and barriers to the
proposed shared care model.
Focus groups and interviews were conducted using a
topic guide to ensure that discussions cover the same
issues but with the ﬂexibility to allow new issues of
importance to the informants to emerge. Discussions were
audio-recorded and transcribed verbatim, and will be
analysed thematically using constant comparative
techniques.
Implementation and trial management
The web application A secure web-based application was
developed to allow participants to take part in the trial
remotely. Participation in the trial was managed entirely
through the web application, with the application secured
by password protection.
The database underpinning the web application
managed recruitment, consent, and the presentation of
vignettes allocated to each participant including the
training sets of vignettes. As participants assessed
vignettes, the application recorded their responses to
questions about the individual features of index images as
well as the overall lesion classiﬁcation status. Pop-up
prompts prevented data entry or key stroke errors. The
systems presented a summary of the participant’s
responses, together with any query, when the lesion
status classiﬁcation was entered (Figure 2). The
participant either conﬁrmed that the responses were
correct or made changes and, ﬁnally, assigned a score
from 1 to 5 to describe their conﬁdence in the assessment
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(1=not conﬁdent at all and 5=very conﬁdent). Once a
participant had conﬁrmed their responses, none of the
data could be changed.
The web application also gave the trial management
team tools for managing and monitoring the conduct of
the trial, including both an individual’s progress and the
progress of the participants collectively. Additionally, the
application provided an electronic delegation log and
electronic sign-off of any study amendments for research
governance purposes.
Selection and recruitment of participants Information about
the trial was publicised in optometry journals and forums
to attract optometrists and circulated to ophthalmologists
who are members of the United Kingdom and Welsh
medical retina groups. Potential participants could read the
participant information sheet and register an interest in
joining the trial through the ECHoES trial public website.25
Once a participant had registered an interest, the study
team checked their eligibility against the General Medical
Council and General Optical Council registries. Eligible
participants were then sent a study consent form by
e-mail.
Sample size
With respect to the primary outcome, the trial was
designed to answer the non-inferiority question ‘Is the
performance of optometrists as good as that of
ophthalmologists?’ A sample of 288 vignettes was chosen
to have at least 90% power to test the hypothesis that the
proportion of vignettes for which lesion status was
correctly classiﬁed by the optometrist group was no more
than 10% lower than the proportion correctly classiﬁed
identiﬁed by the ophthalmologist group, if the
proportion of vignettes for which lesion status was
correctly classiﬁed by the ophthalmologist group was at
least 95%. This sample size calculation assumed that
each vignette would be assessed by only one
ophthalmologist and one optometrist. However, as each
vignette was assessed seven times by each group, the
trial in fact has 90% power to detect non-inferiority for
lower proportions of vignettes correctly classiﬁed by the
ophthalmologist group.
Plan for statistical analyses
All primary and secondary outcomes will be analysed
using mixed-effect regression models, adjusting for the
order the vignettes were viewed as a ﬁxed effect
(tertiles: 1–14, 15–28, and 29–42), and participant and
vignette as random effects. All outcomes are binary and
as such will be analysed using logistic regression with
group estimates presented as odds ratios with 95%
conﬁdence intervals. The sensitivity and speciﬁcity of
the primary outcome will also be presented. In addition
to the group comparisons, the inﬂuence of key vignette
information on participants’ ability to assess the
primary outcome correctly will be investigated using
Poisson regression. Further details will be included in
the statistical analysis plan.
Trial status
Recruitment has closed and data are being
analysed. A total of 155 health-care professionals,
Table 2 Strengths and limitations of the ECHoES study design
Strengths Limitations
Real life data
(IVAN data set)
Data used are from many centres, wide range of
participants so likely to representative
OCT technology was not state of the art when IVAN was
carried out. Newer OCT equipment that produces images
with better resolution would now be available to
Optometrists. Uncertain whether participants’ risk taking
for vignettes is similar to real life
Traininga Delivered identically to all participants in a format that
could easily be accessed by large numbers of
optometrists multiple times
Developed pragmatically, on the basis of knowledge/
skills considered important for the task but also according
to what we thought the NHS would ‘pay’ for training if
implemented
Health-care
professionals
Real life participants, although volunteers (remunerated
for their time but unlikely to cover full cost).
Optometrists likely to be enthusiasts, interested in
providing shared care—but also likely to be true if
shared care were offered/commissioned
Health economics Difﬁcult to quantify investment required by an
optometrists practice to set up doing shared care
a If optometrists are found to be inferior to ophthalmologist one could almost certainly argue that this was because the training provided in the trial was
inadequate. This possibility will also be investigated through the qualitative research.
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72 ophthalmologists, and 83 optometrists, registered an
interest, of whom 62 ophthalmologists and 67
optometrists consented, and 125 started the training
phase (Figure 3). As planned, 96 participants (48 from
each profession) completed the trial and constitute the
analysis population. There are no missing data.
Discussion
The ECHoES trial is funded through the rapid trials
funding call advertised by the National Institute for
Health Research (NIHR) Health Technology Assessment
(HTA) programme in October 2011. The intention was to
commission projects that would inﬂuence clinical practice
in the NHS within 3–4 years. In addition to the novel
design of the ECHoES trial, one of the main challenges
has been the requirement to carry out the research in a
short time period.
The ECHoES trial design has several advantages over a
conventional randomised trial in which recruitment of
patient participants would have had considerable
resource implications, been costly, time consuming and
potentially unacceptable to patients with nAMD. The data
collection element was small; it consisted mainly of
participants’ responses to questions about image features,
lesion status classiﬁcations, referral decisions, resource
use and costs. It used very little paper because data were
entered directly into the web application and most of the
trial related administration was also carried out
electronically. Very few face-to-face meetings were
required to develop the vignettes and the reference
standard was created mainly by the experts using the web
application. Trial administration and participant
correspondence/progression through the trial was
managed electronically so there are negligible
archiving costs.
Table 2 shows some of the strengths and limitations to
the ECHoES study design. A key challenge was the
paucity of suitable baseline and index image pairs,
requiring the same vignettes to be used for training
purposes as well as for the main trial assessments.
We avoided any bias by excluding a participant’s
main trial vignette assessments from their training
vignettes. However, this restriction meant that
standby participants could not assess any training
vignettes until the study team knew which existing
participant they were replacing. Since no similar study
has been previously attempted, we had to make
assumptions about the effectiveness of training and
the number of participants required to ensure that
48 from each profession would complete their main
assessments.
This trial is of signiﬁcant interest to the NHS as it
addresses the question of whether community
optometrists can make retreatment decisions for patients
with quiescent nAMD to the same standard as hospital
ophthalmologists.
Summary
What was known before
K The role of a conventional parallel-group randomised
controlled trial as the gold standard method for
evaluating the effectiveness of an intervention is well
established.
K It can be difﬁcult to recruit to conventional trials of
potentially more efﬁcient ways to deliver health services
(such as shared care) because patients worry that they may
receive substandard care.
K Conventional trials that change policy or practice usually
have to be large, take a long time, are expensive to
complete and sponsorship arrangements can be complex
and time consuming.
What this study adds
K In the ﬁeld of medical retina, vignettes compiled from
images and data collected for research or clinical
purposes can provide a realistic way to emulate
real-life clinical decision-making in the absence of a
patient.
K Trials can be carried out to test the ability of health-care
professionals to make clinical decisions using
vignettes.
K It is possible to recruit quickly to a virtual trial of this kind,
and carry out the entire trial in short duration, at low cost
and without risk to patients, compared to doing a
conventional randomized controlled trial.
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